Nine out of ten drugs that emerge from preclinical development fail in clinical trials. Organoid models offer a promising solution by enhancing the biological relevance and predictive power of early-stage drug development, helping researchers identify effective therapies more efficiently and with greater accuracy.
Download this compendium to learn:
- How organoids improve preclinical model accuracy and clinical predictability
- How patient-derived organoids advance personalized cancer treatment and drug testing
- How organoid biobanks drive rare disease, infectious disease, and cancer research
